Lonza

📰 Weekend read Navigating the evolving pharmaceutical landscape, understanding the integration of cutting-edge technology into drug development and manufacturing is crucial. "Drug services firms begin embracing AI" (https://lnkd.in/dSXGGBxa) article from C&EN offers valuable insights into how leading CDMOs are leveraging AI and automation to enhance efficiency, accelerate timelines, and ensure superior quality in drug synthesis and quality control.🔬✨ As highlighted by our colleague Jan Vertommen, PhD, these advancements directly impact the speed and reliability of bringing critical therapies to market. A valuable read to understand the future of our drug development.

Heading to the Global Drug Delivery & Formulation Summit 2025? Don’t miss Adi Kaushal’s talk on Wednesday, 4 June: "Sustainable and Integrated Pathway to Material-Sparing ASD Formulation and Process Development." Adi will explore how a material-sparing hot melt extrusion (HME) screening approach enables efficient, parallel assessment with spray-dried dispersions. He’ll also cover sustainable innovations in ASD manufacturing. We’re looking forward to connecting. Come meet us at Booth 13. Join us at the #DDFSummit to hear how we are helping our customers advance their challenging molecules, faster. #DrugDelivery #HotMeltExtrusion #AdvancedSynthesis #DDFSummit

We have just launched our Design2Optimize™ platform, to enhance the process development and manufacturing of small molecule APIs. The platform helps to address the challenge of increasingly complex small molecule API routes, which now often consist of at least 20 synthetic steps. It helps drug developers to build predictive models at speed, even for complex or poorly understood reactions where the mechanism is not definitively known. By generating a digital twin of each process, the platform enables scenario testing in situ without the need for further physical experimentation. Combining the Design2Optimize™ platform with Lonza’s award-winning AI-enabled route scouting service and high-throughput experimentation (HTE) to rapidly test and compare reaction conditions, Lonza’s integrated approach streamlines development, enhances process understanding, and accelerates the journey from molecule design to market. Read more here: https://lnkd.in/dCtbjRrA #Lonza #PharmaceuticalInnovation #SmallMoleculeAPI #ProcessDevelopment #DrugDevelopment

🔬 Biologics In Focus | May 2025 Edition is now live! This month, we’re proud to unveil a major innovation in biologics manufacturing: GSquad® Pro, our next-generation gene expression vector. The novel LHP-1 promoter features enhanced control and improved titer and supports the efficient production of complex biologics, including bispecific antibodies and fusion proteins. In addition to this breakthrough, we explore: ✔️ Advances in synthetic production-phase promoters ✔️ Strategies for immunogenicity risk mitigation ✔️ Roche’s latest move to expand U.S. biologics production ✔️ And a look ahead to our June webinar on early biologics development strategies Join over 118,000 subscribers staying informed on the science, strategy, and innovations shaping the future of biologics. 👉 Subscribe now and share with your network https://lnkd.in/e9GgYKfk #IntegratedBiologics #BiologicsInFocus #Biotechnology #ThePeoplePoweringBiologics

Looking For an Opportunity? At Lonza, your skills could help transform the world of life science. Whether you want to manufacture vital new drugs, or streamline processes that advance the healthcare industry, joining our talent community is the easiest way to find the right role. Register now: https://lnkd.in/dpXkY3Tb #Careers #Hiring #JoinOurTeam

Continuous manufacturing is unusual in the world of API manufacture, where the norm is to use batch reactors. Yet, continuous processes are routinely used to make commodity chemicals on a much larger scale. Our experts here at Lonza believe there is great potential to implement more continuous processes when making APIs. Lonza Principal Chemist, Bernhard Gutmann, is giving a webinar that will look at the potential advantages of switching to continuous processing. These include lower costs, higher yields, and more robust processes. He’ll also present a number of case studies that will highlight its versatility in API manufacturing. You can register for the free webinar to learn more about the potential of continuous processing in pharma manufacturing. Date: Wednesday , 25 June Time: 4pm CEST/ 10am EDT. Register: https://lnkd.in/d2MNt42y #ContinuousFlow #Lonza #AdvancedSynthesis #CDMO

📢 Join us at the Compaction Simulation Forum (June 9-11, San Francisco) and catch these key presentations from our experts: 🗓️ Monday, June 9, 1:00pm - 5:00pm PDT: Aaron Johnson, PhD, R&D Cheminformatics Data Scientist Advanced Chemistry - "AI applications in pharmaceutical development – streamlining cocrystal design and API route optimization." 🗓️ Tuesday, June 10, 1:00pm - 5:00pm PDT: Allison DuRoss, Manager, Bioavailability Enhancement Engineering - Co-Chairing the Tuesday session - "Outsourcing compaction simulation for process design, optimization, and risk mitigation in manufacturing." 🗓️ Tuesday, June 10, 1:45pm - 2:10pm PDT: Sadie Fallis, Engineer III, Product Development - "A material-sparing over-lubrication risk assessment: correlation with tablet press performance." 🗓️ Wednesday, June 11, 4:00pm - 4:30pm PDT: Aaron Johnson, PhD, R&D Cheminformatics Data Scientist Advanced Chemistry will participate in a Panel discussion on AI applications. 💰 Don't miss out! A 25% discount on your registration fee is still available. Connect with our team by reaching out to Tanner Call or Allison DuRoss to get the discount. 🤝 #CompactionSimulation #PharmaceuticalAI

We’re delighted to share that one of our inhalation experts,  Beatriz Noriega Fernandes, PhD, will be presenting at the Global Pulmonary Health: Inhalation & Respiratory 2025 Conference on 22 May in Munich, Germany. Her talk, “Advancements in Dry Powder Inhalation Technology: Enhancing Patient Outcomes Through Formulation,” explores how a clear Target Product Profile (TPP) shapes the development of Dry Powder Inhalers (DPIs) to ensure effective drug delivery to the lungs and better patient outcomes. Beatriz will also discuss different types of DPI technologies and their appropriate applications discuss various DPI technologies and their use cases, closing with a insightful case study on the development of dry powder inhaled vaccines. We look forward to seeing you there! #GPH2025 #AdvancedSynthesis #Inhalation

What an incredible experience at ASGCT 2025    Our time at the conference was filled with insightful conversations, groundbreaking science, and meaningful connections that are shaping the future of gene and cell therapy.    We were inspired by the passion and innovation across the industry—from advances in delivery technologies and regulatory progress, to patient-centered approaches that are driving real impact. It’s clear that collaboration is at the heart of every breakthrough.    A big thank you to everyone who stopped by, shared ideas, and contributed to the vibrant energy of the event. We’re leaving ASGCT energized and more committed than ever to pushing the boundaries of what’s possible.    If you’d like to continue your conversation with one of our team, please contact our team here: https://lnkd.in/eMYDVTmU   #ASGCT2025 #GeneTherapy #CellTherapy #Biotech #CellandGene 

With so many molecules entering the pharma development pipeline nowadays being poorly soluble, finding a dosage form that gives adequate bioavailability can be a real challenge. It’s something the Lonza team in Bend, Oregon has put a real focus on in recent years. They use tools such as physiologically based biopharmaceutics modeling, or PBBM, to help them find alternative solid forms with better solubility. PBBM software, such as GastroPlus® from Simulations Plus, Inc., allows them to simulate the interplay of a molecule’s physio-chemical, metabolism and excretion properties with the target physiology and formulation attributes. Combining these with carefully selected in vitro measurements, they can evaluate the likelihood that an enabled solid form will be successful, cutting down the number of experiments they have to run. Josh Marsh and Abhijeet Sinha, two of the Bend team, are giving a webinar that will look into this important topic in much more detail. It’s happening on Thursday, 5 June at 16:00 CEST/10:00 EDT, and is free to attend. Please register at https://bit.ly/4k3LOD4 and join them to find out more about how Lonza searches for the best enabled solid forms. #SFS #PBBM #AdvancedSynthesis #CDMO #Lonza